User login
Key clinical point: Emergent vs elective surgery after bevacizumab exposure was associated with a significantly higher mortality in patients with metastatic colorectal cancer (mCRC), with an interval of >4 weeks between the surgery and last bevacizumab infusion being protective against additional mortality risk.
Major finding: Emergent vs elective surgery was an independent risk factor for 60-day mortality (adjusted odds ratio [aOR] 1.912; 95% CI 1.220-2.996), with elective surgery within 29-56 days (aOR 0.522; 95% CI 0.310-0.877) and >57 days (aOR 0.540; 95% CI 0.333-0.873) vs within 28 days of last bevacizumab infusion being associated with a significantly lower 60-day mortality.
Study details: The data come from a retrospective study including 2047 patients with mCRC who underwent surgery (emergent 13.78%; elective 86.22%) within 1 year of receiving bevacizumab.
Disclosures: This study was funded by Kaohsiung Veterans General Hospital, Taiwan. No conflicts of interest were declared.
Source: Chen YH et al. Mortality of patients with metastatic colorectal cancer who received elective or emergent operation after exposure to bevacizumab: A nationwide database study. Eur J Surg Oncol. 2022 (Oct 1). Doi: 10.1016/j.ejso.2022.09.018
Key clinical point: Emergent vs elective surgery after bevacizumab exposure was associated with a significantly higher mortality in patients with metastatic colorectal cancer (mCRC), with an interval of >4 weeks between the surgery and last bevacizumab infusion being protective against additional mortality risk.
Major finding: Emergent vs elective surgery was an independent risk factor for 60-day mortality (adjusted odds ratio [aOR] 1.912; 95% CI 1.220-2.996), with elective surgery within 29-56 days (aOR 0.522; 95% CI 0.310-0.877) and >57 days (aOR 0.540; 95% CI 0.333-0.873) vs within 28 days of last bevacizumab infusion being associated with a significantly lower 60-day mortality.
Study details: The data come from a retrospective study including 2047 patients with mCRC who underwent surgery (emergent 13.78%; elective 86.22%) within 1 year of receiving bevacizumab.
Disclosures: This study was funded by Kaohsiung Veterans General Hospital, Taiwan. No conflicts of interest were declared.
Source: Chen YH et al. Mortality of patients with metastatic colorectal cancer who received elective or emergent operation after exposure to bevacizumab: A nationwide database study. Eur J Surg Oncol. 2022 (Oct 1). Doi: 10.1016/j.ejso.2022.09.018
Key clinical point: Emergent vs elective surgery after bevacizumab exposure was associated with a significantly higher mortality in patients with metastatic colorectal cancer (mCRC), with an interval of >4 weeks between the surgery and last bevacizumab infusion being protective against additional mortality risk.
Major finding: Emergent vs elective surgery was an independent risk factor for 60-day mortality (adjusted odds ratio [aOR] 1.912; 95% CI 1.220-2.996), with elective surgery within 29-56 days (aOR 0.522; 95% CI 0.310-0.877) and >57 days (aOR 0.540; 95% CI 0.333-0.873) vs within 28 days of last bevacizumab infusion being associated with a significantly lower 60-day mortality.
Study details: The data come from a retrospective study including 2047 patients with mCRC who underwent surgery (emergent 13.78%; elective 86.22%) within 1 year of receiving bevacizumab.
Disclosures: This study was funded by Kaohsiung Veterans General Hospital, Taiwan. No conflicts of interest were declared.
Source: Chen YH et al. Mortality of patients with metastatic colorectal cancer who received elective or emergent operation after exposure to bevacizumab: A nationwide database study. Eur J Surg Oncol. 2022 (Oct 1). Doi: 10.1016/j.ejso.2022.09.018